A Phase I Clinical Trial of JH013 Injection

A Phase I Clinical Trial of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JH013 Injection in Healthy Subjects

This is a phase I clinical trial with a single dose escalation to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of JH013 injection in healthy subjects

Study Overview

• Status: Not yet recruiting
• Conditions: Healthy Subjects (HS)
• Intervention / Treatment: Drug: JH013 injection; Drug: Placebo

Detailed Description

Four dose groups were set up, 75 mg, 150 mg, 300 mg, and 500 mg, respectively. Eight subjects (6 subjects received JH013 injection, 2 subjects received placebo) were planned to be included in each dose group for subcutaneous administration.The safety and tolerability within 48 hours after administration were first observed in each dose group with 2 subjects (1 subject receiving JH013 injection and 1 subject receiving placebo),after that, the remaining 6 subjects (5 receiving JH013 injection and 1 receiving placebo) were enrolled. Each subject may only participate in this trial in one dose group, and the next higher dose trial will only be allowed after it has been determined that the previous dose has been well safe and tolerated within 28 days of dosing (as determined by an independent, unblinded third-party physician in conjunction with the investigator and sponsor). When the safety evaluation meets the termination criteria during the dose escalation process, the dose between the dose group and the previous dose group can be returned if necessary after discussion by the investigator and the sponsor, and the maximum safe tolerated dose can be explored again. When the dose is escalated to the highest dose set by the protocol and the dose termination criteria are not met, it is up to the investigator and the sponsor to discuss whether to expand to a higher dose.

• Study Type: Interventional
• Enrollment (Estimated): 32
• Phase: Phase 1

Contacts and Locations

• Study Contact: Name: Wang Yucheng, Master; Phone Number: 010-51571020; Email: wangyucheng@biotechplc.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• Healthy adult male or female aged 18-55 years (age including cut-off values);
• There were no abnormalities in clinically significant vital signs, physical examination, laboratory tests, and 12-lead ECG;
• Weight ≥ 50 kg for males and ≥45 kg for females; Body mass index (BMI) between 18.0 and 26 kg/m2 (including cut-off values, body mass index = weight/height2);
• Females of potential childbearing potential with a negative blood β-HCG test within 72 hours prior to dosing (postmenopausal women who have amenorrhea for at least 12 months are considered non-childbearing and women who are known to have undergone hysterectomy, bilateral oophorectomy, bilateral salpingectomy, or ligation, and a pregnancy test is not required);
• Subjects understand and comply with the study process, participate voluntarily, and sign the informed consent form

Exclusion Criteria:

• Subject has a history of malignancy prior to screening, or has been screened for malignancy, and the possibility of malignancy cannot be reasonably ruled out
• Subject has a history of autoimmune disease prior to screening
• γ interferon release assay results ≥ 2 times the upper limit of normal
• Any history of infection requiring hospitalization or receiving antivirals, antibiotics, antifungals, antiparasitic drugs, or vaccinations within 4 weeks prior to the application of the study drug
• Those who have positive test results for human immunodeficiency virus (HIV) antibody, hepatitis B virus (HBV) surface antigen, hepatitis C virus (HCV) antibody or syphilis antibody
• Patients with a history of previous and/or current heart disease (including New York Heart Association Class III/IV heart failure), gastrointestinal, renal, endocrine, neurological, autoimmune, hematologic (including pancytopenia, aplastic anemia or anaemia, etc.), metabolic (including diabetes), severe lung disease and psychiatric illness
• History of organ transplantation: such as heart, lung, kidney, liver, or hematopoietic stem cell transplantation

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Triple

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: JH013 injections 75mg; 6 subjects receive JH013 at a dose of 75 mg and 2 subjects receive the same volume placebo	Drug: JH013 injection; JH013 injection is a BAFF-R inhibitor monoclonal antibody; Other Names: JH013; Drug: Placebo; JH013 injections placebo; Other Names: JH013 Placebo
Experimental: JH013 injections 150mg; 6 subjects will receive JH013 injections 150mg，2 subjects receive the same volume placebo	Drug: JH013 injection; JH013 injection is a BAFF-R inhibitor monoclonal antibody; Other Names: JH013; Drug: Placebo; JH013 injections placebo; Other Names: JH013 Placebo
Experimental: JH013 injections 300mg; 6 subjects receive JH013 at a dose of 300 mg and 2 subjects receive the same volume placebo	Drug: JH013 injection; JH013 injection is a BAFF-R inhibitor monoclonal antibody; Other Names: JH013; Drug: Placebo; JH013 injections placebo; Other Names: JH013 Placebo
Experimental: JH013 injections 500mg; 6 subjects receive JH013 at a dose of 500 mg and 2 subjects receive the same volume placebo	Drug: JH013 injection; JH013 injection is a BAFF-R inhibitor monoclonal antibody; Other Names: JH013; Drug: Placebo; JH013 injections placebo; Other Names: JH013 Placebo

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Safety metrics	Including Adverse events defined by CTCAE 5.0（Common Terminology Criteria for Adverse Events Version 5.0) Version 5.0）	from Administration to Day57.

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
t1/2	Half-life	from Administration to Day57.
Cmax	maximum plasma concentration	from Administration to Day57.
CD45+CD19+ B cell	Detection CD45+CD19+ B cell count and ratio in blood	from Administration to Day57.
B cell activation factor (BAFF)	Detection B cell activation factor (BAFF) in serum	from Administration to Day57.
JH013 antibody	Detection of JH013 antibody occupancy in serum	from Administration to Day57.
CD45+CD3+T cell	Detection of CD45+CD3+T cell count and ratio blood	from Administration to Day57.
Drug immunogenicity	Detection of anti-drug antibodies in serum	from Administration to Day57.

Collaborators and Investigators

• Sponsor: Biotech Pharmaceutical Co., Ltd.
• Investigators: Principal Investigator: chen Rui, Dr, Peking Union Medical College Hospital

Study record dates

Study Major Dates

• Study Start (Estimated): October 31, 2024
• Primary Completion (Estimated): June 30, 2025
• Study Completion (Estimated): December 31, 2025

Study Registration Dates

• First Submitted: September 28, 2024
• First Submitted That Met QC Criteria: October 7, 2024
• First Posted (Estimated): October 9, 2024

Study Record Updates

• Last Update Posted (Estimated): October 9, 2024
• Last Update Submitted That Met QC Criteria: October 7, 2024
• Last Verified: October 1, 2024

More Information

Terms related to this study

• Keywords: Dose escaltion
• Other Study ID Numbers: BPL-JH013-HV-1001

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No